Schweizerischer Nationalfonds / Fonds national suisse
She deciphers how tomato roots communicate
plus
Actualités sur CRISPR
-
Langue:
Anglais
- Médias:
- Période:
- Période:Totale
Schweizerischer Nationalfonds / Fonds national suisse
Avoiding burnout of white blood cells
plusAvectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications'
Dublin (ots/PRNewswire) - SOLUPORE® technology enables the next-generation of gene-modified cell therapies Irish based cell engineering company, Avectas today announces the publication of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy ...
plusAvectas Announces Issuance of U.S. Patent for Cell Engineering Technology by the U.S. Patent and Trademark Office
Dublin (ots/PRNewswire) - Avectas announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,612,042, which is central to the company's cell engineering technology, Solupore® and expands Avectas' global Intellectual Property portfolio. This patent covers an approach for ...
plusOxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment
Oxford, England (ots/PRNewswire) - Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing tests, with the potential to ...
plusMerck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...
plus
1